(Alliance News) - The following is a round-up of updates and earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Scancell Holdings PLC on Monday said it has partnered with the NHS Cancer Vaccine Launch Pad, to accelerate patient recruitment into the fourth cohort of its phase 2 scope study for a targeted melanoma vaccine. Read More
(Alliance News) - Stock prices in London were in the green at midday on Monday, while Beijing has warned the UK against "politicising" an unfolding spat over the future of Chinese-owned British Steel. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday. Read More
Scancell Holdings PLC - Oxford, UK-based pharmaceutical firm - Pretax loss multiplies to GBP13.8 million in the six months to October 31 from GBP3.6 million a year prior. R&D expenses rise to GBP8.0 million from GBP5.7 million, administrative expenses edge up to GBP2.5 million from GBP2.4 million. Bottom line hit by GBP4.5 million loss relating to revaluation of derivative liability compared to GBP4.9 million gain a year prior. Cash balances at October 31 are GBP9.1 million compared to GBP14.8 million at April 30, 2024. Sees cash runway to the second half of 2026 beyond multiple clinical milestones. Read More
(Alliance News) - Scancell Holdings PLC on Thursday said its cancer vaccine had achieved early validation for clinical use. Read More
Scancell Holdings PLC - Oxford, England-based developer of immunotherapies - Raises GBP10.3 million from the placing and direct subscription of 97.7 million shares at 10.5 pence each. The amount beats the target set by Scancell late Wednesday. It had hoped to raise at least GBP8.5 million. The placing is run by Panmure Liberum Ltd. Scancell hopes to raise a further GBP1 million from a retail share offer at the same price via the Winterflood Retail Access Platform. Read More
(Alliance News) - Scancell Holdings PLC on Monday reported positive data from an ongoing trial on patients receiving a treatment combination for advanced melanoma, a skin cancer. Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced this week and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Scancell Holdings PLC on Wednesday announced a major international biotechnology company will exclusively evaluate a Scancell investigational anti-glycan monoclonal antibody for development of novel therapeutic products. Read More
(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Scancell Holdings PLC on Tuesday reported a narrowed loss as it gained on the revaluation of derivative liability. Read More
Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease said - Receives approval from UK's Medicines & Healthcare products Regulatory agency to add a third cohort to the Scope trial. Says the cohort will consist of 43 melanoma patients who will receive iSCIB1+ with doublet therapy, consisting of ipilimumab, under the brand name Yervoy, plus nivolumab, under the name Opdivo. "Exceptional" results from the first 13 patients receiving SCIB1 in the ongoing Scope trial, with an objective response rate of 85%, indicate a high probability of success in this cohort, which is expected to complete in the second quarter of 2024. Meanwhile, recruitment into the iSCIB1+ cohort is expected to be complete by the end of the second quarter as well, with early data expected in the third quarter of 2024. Read More
(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of shares. Read More
Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease - Raises GBP10.7 million from the placing and subscription of 97.0 million new shares at 11 pence each. The placing is run by Stifel Nicolaus Europe Ltd and WG Partners LLP. Scancell also plans an open offer of shares at the same price to raise up to another GBP2.0 million. Scancell says the placing was oversubscribed and upsized as a result. After the London market close on Thursday, Scancell had announced plans to raise just GBP6 million in the placing. It says the raise was led by "new institutional and life science specialist investors". Read More